ArticleAdvances in therapy2019
Second-Generation Trabecular Micro-Bypass Stents as Standalone Treatment for Glaucoma: A 36-Month Prospective Study.
Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04092400 (Prospective Observational Study of Patients Implanted With Micro-invasive Glaucoma Surgical), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Observational Study of Patients Implanted With Micro-invasive Glaucoma Surgical (MIGS) Devices at the National University Hospital, Singapore
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Minimally Invasive Glaucoma Surgery: Where Is the Evidence?Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Pooled it
- Retrospective analysis of indications and outcomes of trabecular micro-bypass stent implantation in Indian eyes.Indian journal of ophthalmology · 2026Article
- Cataract surgery with and without trabecular micro-bypass stent in primary angle-closure glaucoma: a multi-centre cohort study.Eye (London, England) · 2025Article
- Five-Year Outcomes of iStent inject Implantation With or Without Phacoemulsification in Eyes with Open-Angle Glaucoma.Ophthalmology and therapy · 2025Article
- Visual Function After Schlemm's Canal-Based MIGS.Journal of clinical medicine · 2025Review
- Interventional glaucoma: Rethinking glaucoma treatment paradigms in the Asian context.Indian journal of ophthalmology · 2025Review
- Taiwan's first clinical reports on the surgical effect of high-frequency deep sclerotomy for treating primary open-angle glaucoma.BMC ophthalmology · 2025Article
- Comparison of the Intraocular Pressure-Lowering Effect of Minimally Invasive Glaucoma Surgery (MIGS) iStent Inject W and Hydrus-The 12-Month Real-Life Data.Diagnostics (Basel, Switzerland) · 2025Article
- Meta-Analysis of MINIject vs. Two iStents as Standalone Treatment for Glaucoma with 24 Months of Follow-Up.Journal of clinical medicine · 2024Review
- Article
- 7-Year Efficacy and Safety of iStent inject Trabecular Micro-Bypass in Combined and Standalone Usage.Advances in therapy · 2024Article
- 36-Month Outcomes from the Prospective GEMINI Study: Canaloplasty and Trabeculotomy Combined with Cataract Surgery for Patients with Primary Open-Angle Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Preventing Blindness with Early Cataract Surgery and Micro-Invasive Glaucoma Surgery in Patients Over 50: Guidance for Patients, Physicians and World Governments in Dealing with Glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Minimally Invasive Glaucoma Surgery: Safety of Individual Devices.Journal of clinical medicine · 2022Review
- Standalone Implantation of 2-3 Trabecular Micro-Bypass Stents (iStent inject ± iStent) as an Alternative to Trabeculectomy for Moderate-to-Severe Glaucoma.Ophthalmology and therapy · 2022Article
- Multicenter Effectiveness and Disease Stability Through 3 Years After iStentTrabecular Micro-Bypass with Phacoemulsification in Glaucoma and Ocular Hypertension.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- iStent versus iStent inject implantation combined with phacoemulsification in open angle glaucoma.Indian journal of ophthalmology · 2021Article
- iStent for Adults With Glaucoma: A Health Technology Assessment.Ontario health technology assessment series · 2021Article
- Two-Year Comparative Outcomes of First- and Second-Generation Trabecular Micro-Bypass Stents with Cataract Surgery.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Treatment Success Across Different Levels of Preoperative Disease Burden: Stratified Two-Year Outcomes from the Pivotal Trial of iStentClinical ophthalmology (Auckland, N.Z.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionTo evaluate long-term outcomes following stand-alone implantation of two second-generation trabecular micro-bypass stents (iStent inject
methodsEyes with POAG, pseudoexfoliative glaucoma (PXG), appositional narrow-angle glaucoma (NAG, with open-angle configuration in the area of implantation), or secondary glaucoma were included in this prospective, non-randomized, consecutive case series. All eyes underwent ab interno iStent inject implantation as a sole procedure. Assessments through 36 months included IOP, medications, corrected distance visual acuity (CDVA), secondary glaucoma surgeries, and complications and adverse events.
resultsTwo iStent inject stents were implanted in 44 consecutive eyes (POAG = 38, PXG = 4, appositional NAG = 1, secondary neovascular glaucoma = 1) of 31 patients, and 33 eyes had 36-month follow-up data. Preoperative mean IOP was 25.3 ± 6.0 mmHg on a mean of 2.98 ± 0.88 medications, with 75% of eyes on 3-5 medications, no eyes medication-free, and 50% of eyes with history of prior glaucoma surgery. At 36 months postoperatively, mean IOP reduced by 42% to 14.6 ± 2.0 mmHg (p < 0.0001) and 87.9% of eyes achieved an IOP reduction of ≥ 20% versus preoperatively. In addition, 97% of eyes reached IOP ≤ 18 mmHg (vs. 9.1% preoperatively; p < 0.0001) and 70.0% of eyes reached IOP ≤ 15 mmHg (vs. 2.3% preoperatively; p < 0.0001). Mean medication burden decreased by 82% to 0.55 ± 0.79 (p < 0.0001), and 61% of eyes became medication-free. All eyes maintained or decreased their 36-month medication burden versus preoperatively. Safety was favorable, including minimal adverse events and stable CDVA through 36 months postoperatively.
conclusionThis real-world cohort of glaucomatous eyes with substantial preoperative disease burden experienced significant, sustained, safe IOP and medication reductions through 36 months following stand-alone iStent inject implantation.
fundingArticle processing charges and writing assistance were provided by Glaukos Corp. (San Clemente, CA, USA).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.